Medical Historian Prescribes, Fact Checks for Television Medical Historian Prescribes, Fact Checks for Television
Who takes the call when Hollywood needs help with a medical script? In one case, the director of the Museum of Vision helped out, and plans to open to the public in 2020 are underway.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 18, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Childhood blindness therapy shows 'very promising' results
(University College London) A new therapy aimed at improving the sight of people with one of the most common forms of childhood blindness, has shown 'very promising' initial results, according to a study involving UCL researchers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 18, 2018 Category: International Medicine & Public Health Source Type: news

AMD Monitoring Comes Home: The Promise of Remote Tech AMD Monitoring Comes Home: The Promise of Remote Tech
Current software helps track patients'AMD progression. What's coming next may enable us to intervene earlier with tailored treatments.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 17, 2018 Category: Consumer Health News Tags: Ophthalmology Article Source Type: news

Nicox teams up with Chinese firm to develop and sell glaucoma drug
French ophthalmology company Nicox and Chinese firm Ocumension Therapeutics said on Monday they had signed an exclusive license agreement to develop and sell a yet-to-be approved Nicox drug to treat glaucoma in China. (Source: Reuters: Health)
Source: Reuters: Health - December 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Injection improves vision in a form of childhood blindness
(University of Pennsylvania School of Medicine) A new treatment for patients with a form of congenital retinal blindness has shown success in improving vision, according to results published today in Nature Medicine led by researchers at the Scheie Eye Institute in the Perelman School of Medicine at the University of Pennsylvania. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 17, 2018 Category: International Medicine & Public Health Source Type: news

What Causes Hyperpigmentation?
Discussion Skin color is primarily due to genetic factors. Melanocytes are usually found in skin in the basal layer of the epidermis which is also where the melanin usually lies. There are a range of normal skin phenotypes that have been described by Fitzpatrick and range from I-VI: I – pale white skin, blond hair, blue eyed, does not tan, always burns II – fair skin, blue eyed, tans poorly, burns easily III – darker white skin, burns initially then tans IV – light brown skin, tans easily, burns minimally V – brown skin, tans darkly easily, burns rarely VI – dark brown skin, alway...
Source: PediatricEducation.org - December 17, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

AK-Pentolate (Cyclopentolate Hydrochloride Ophthalmic Solution) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 15, 2018 Category: Drugs & Pharmacology Source Type: news

Q & A: Albinism Strips Pigment From the Body, Including the Eyes
The pigment shortage may cause eyes to appear pink or red. In fact, the coloring results from exposed blood vessels. (Source: NYT Health)
Source: NYT Health - December 14, 2018 Category: Consumer Health News Authors: C. CLAIBORNE RAY Tags: Eyes and Eyesight Albinism Source Type: news

Age-Related Macular Degeneration: 5 Things to Know Age-Related Macular Degeneration: 5 Things to Know
A guide to the latest on this chronic disease, from emerging treatments to the risk factors to be on the lookout for.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 14, 2018 Category: Consumer Health News Tags: Ophthalmology Commentary Source Type: news

Medical News Today: Do I have night blindness?
Night blindness occurs when an existing eye condition leads to an inability to see clearly in dim light. Treatments depend on the cause but often involve managing the underlying condition. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 14, 2018 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

Cava, Optoro and a bunch of biotechs: The top 10 venture deals of 2018
It is likely that 2018 is the best year for venture capital in recent memory. Some of the most well-known startups in Greater Washington got fresh infusions of venture capital in 2018, propelling growth and fueling acquisitions. Meanwhile some new players broke into the top ranks of VC deals, including recent spinoff Viela Bio. The top 10 deals of the year are a reminder t hat 2018 has been particularly good for larger startups. The region saw $1.42 billion in venture funding through the first three… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 14, 2018 Category: Biotechnology Authors: Andy Medici Source Type: news

EHR-Linked Reminder System for Glaucoma Meds Perceived Useful
FRIDAY, Dec. 14, 2018 -- Patients with glaucoma generally find an electronic health record (EHR)-linked reminder system for glaucoma medications useful, according to a study published online Dec. 13 in JAMA Ophthalmology. Varshini Varadaraj,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 14, 2018 Category: Pharmaceuticals Source Type: news

Cava, Optoro and a bunch of biotechs: The top 10 venture deals of 2018
It is likely that 2018 is the best year for venture capital in recent memory. Some of the most well-known startups in Greater Washington got fresh infusions of venture capital in 2018, propelling growth and fueling acquisitions. Meanwhile some new players broke into the top ranks of VC deals, including recent spinoff Viela Bio. The top 10 deals of the year are a reminder t hat 2018 has been particularly good for larger startups. The region saw $1.42 billion in venture funding through the first three… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 14, 2018 Category: American Health Authors: Andy Medici Source Type: news

Dextenza (Dexamethasone Ophthalmic Insert) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 14, 2018 Category: Drugs & Pharmacology Source Type: news

Medication Errors Resulting in Death Most Common in Elderly
Most common medication error category was omitted medicine or ingredient (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - December 13, 2018 Category: Psychiatry Tags: Cardiology, Dermatology, Endocrinology, Family Medicine, Geriatrics, Gastroenterology, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Critical Care, Emergency Medicine, Nephrology, Neurology, Nursing, Oncology, Ophthalmology, Orthopedics, ENT, Source Type: news

Google launches Thai AI project to screen for diabetic eye disease
Google said on Thursday it had launched an artificial intelligence program in Thailand to screen for a diabetic eye disease which causes permanent blindness. (Source: Reuters: Health)
Source: Reuters: Health - December 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

America's Best Contacts and Glasses opens in Winston-Salem
A new option for eye care and vision apparel has come to Winston-Salem. America’s Best Contacts and Glasses, a brand owned by National Vision Holdings, Inc. (NASDAQ: EYE), is open at 1602 S. Stratford Road, Suite 120. The new site employs a staff of five – an optometrist and other eye care professionals as well as sales, a company spokesperson said.  Eye exams are administered on-site by an independent medical practice within the store, the company said. The new 3,500-square-foot space… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 13, 2018 Category: American Health Authors: John Joyce Source Type: news

Higher Eye Pressure After Anti-VEGF Therapy Needs More Attention Higher Eye Pressure After Anti-VEGF Therapy Needs More Attention
The elevated intraocular pressure (IOP) known to follow intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents may persist in certain patients, according to a report by the American Academy of Ophthalmology (AAO).Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 12, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

A Girl Whose Eyes Appear White in Photos A Girl Whose Eyes Appear White in Photos
Photographs of this 6-year-old girl show'white eyes'that concern her parents. What is your diagnosis?Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 12, 2018 Category: Consumer Health News Tags: Ophthalmology Case Challenge Source Type: news

U.S. Medical Schools See Increase in Diversity
More female, black, and Hispanic matriculants seen after diversity accreditation standards implemented (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - December 12, 2018 Category: Psychiatry Tags: Cardiology, Dermatology, Endocrinology, Family Medicine, Geriatrics, Gastroenterology, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Critical Care, Emergency Medicine, Nephrology, Neurology, Oncology, Ophthalmology, Orthopedics, ENT, Pathology Source Type: news

Seno Medical Instruments touts Imagio breast cancer subtype ID trial results
Seno Medical Instruments today released results from a study of its Imagio opto-acoustc imaging system intended to diagnose breast cancer, touting that both morphologic and functional OA/US features serve as a non-invasive approach to helping distinguish breast cancer molecular subtypes. Results from the study were presented late last month at the Radiological Society of North America’s 2018 annual meeting in Chicago, the San Antonio-based company said. In the study, investigators explored the potential role of functional OA/US imaging-derived hemoglobin de-oxygenation and angiogenesis feature scoring alongside conve...
Source: Mass Device - December 11, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Women's Health Seno Medical Instruments Source Type: news

LumiThera inks Italian Valeda distro deal
LumiThera said today that it inked a deal with ophthalmology distributor Miloftalmica to be the exclusive distributor of the Valeda light delivery system, intended to treat dry age-related macular degeneration, across Italy. Therapy using the Valeda light delivery system consists of a series of light-based treatments to the retinal cells, which Seattle-based LumiThera claims improves energy production and can be used to address inflammation, ischemia and metabolic dysfunction that contribute to the disease. “Our new exciting partnership with LumiThera is fully consistent with the strategy and growth objectives of Mil...
Source: Mass Device - December 11, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Distribution Optical/Ophthalmic LumiThera Source Type: news

Seno Medical points to research at RSNA 2018
Optoacoustic imaging firm Seno Medical Instruments is directing attention to...Read more on AuntMinnie.comRelated Reading: Seno touts study on cost of follow-up breast exams Seno touts study on downgrading breast mass risk Seno touts Imagio results at ARRS 2017 Seno Medical names Miller as senior VP Seno touts optoacoustic breast studies at SABCS (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 11, 2018 Category: Radiology Source Type: news

Chicago eye care startup Opternative changes name
Chicago eye care company Opternative is rebranding itself and changing its name as it aims to better convey its business-to-business offerings to the optometry and eyewear industries. The company, which now goes by Visibly, announced the change Tuesday, saying that the new name “fully embraces the solutions it offers the eye care industry and appropriately represents the broad scope of who it can serve.” Visibly, originally founded in 2012, has become known for its at-ho me, digital vision… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 11, 2018 Category: Biotechnology Authors: Katherine Davis Source Type: news

Feds drop insider trading, perjury charges against ex-AMO chief Mazzo
Federal prosecutors this week dropped perjury and insider trading charges against former Advanced Medical Optics CEO James Mazzo related to AMO’s $2.8 billion acquisition by Abbott (NYSE:ABT) in 2009 in light of two hung juries, according to court documents. Judge Andrew Guilford for the U.S. District Court for the Central District of California ordered a dismissal with prejudice for Mazzo this week, according to court documents. Mazzo faced charges of tipping close friend and neighbor Doug DeCinces, a former Orioles player, about AMO’s then-pending merger (Abbott subsequently...
Source: Mass Device - December 11, 2018 Category: Medical Devices Authors: Fink Densford Tags: Featured Legal News Optical/Ophthalmic Abbott Advanced Medical Optics Insider Trading Source Type: news

Laser pointers should be thrown away, say safety experts
Parents are being warned that their children's eyesight could be at risk. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - December 11, 2018 Category: Consumer Health News Source Type: news

LumiThera Announces a Distribution Agreement for the Valeda Light Delivery System with Miloftalmica in Italy
SEATTLE, Dec. 11, 2018 -- (Healthcare Sales & Marketing Network) -- LumiThera Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, announced a distribution agreement wit... Devices, Ophthalmology, Distribution LumiThera , Miloftalmica, photobiomodulation, Valeda Light Delivery (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 11, 2018 Category: Pharmaceuticals Source Type: news

Atia Vision, A Shifamed Portfolio Company, Closes $10M In Series C Financing
CAMPBELL, Calif., Dec. 10, 2018 -- (Healthcare Sales & Marketing Network) -- Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular accommodating intraocular lens, announced today the c... Devices, Ophthalmology, Venture Capital Atia Vision, Shifamed, intraocular lens (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 10, 2018 Category: Pharmaceuticals Source Type: news

Alembic Pharmaceuticals gets USFDA nod for ophthalmic solution
The company has received approval from the USFDA for its abbreviated new drug application (ANDA) Olopatadine Hydrochloride ophthalmic solution USP, 0.1 per cent, Alembic Pharmaceuticals said in a filing to BSE. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 10, 2018 Category: Pharmaceuticals Source Type: news

UK nerve agent survivor fears poison will soon kill him
A British man who was exposed to the deadly nerve agent Novichok says he is struggling with his eyesight and mobility, and fears the poison will kill him within a decade (Source: ABC News: Health)
Source: ABC News: Health - December 9, 2018 Category: Consumer Health News Tags: Health Source Type: news

U.N. AIDS Agency Is in ‘ State of Crisis ’ and Needs New Leader, Report Says
Experts accused Michel Sidib é , the agency ’ s chief, of having an autocratic style leading to “ ethical blindness ” on harassment and the abuse of power. (Source: NYT Health)
Source: NYT Health - December 7, 2018 Category: Consumer Health News Authors: NICK CUMMING-BRUCE Tags: Acquired Immune Deficiency Syndrome UNAIDS United Nations Sexual Harassment #MeToo Movement Ethics and Official Misconduct Michel Sidibe Source Type: news

Skipping Treatment for Diabetic Retinopathy Carries Risks Skipping Treatment for Diabetic Retinopathy Carries Risks
Drs Jason Hsu and Anthony Obeid on how the 25% of patients lost to follow-up are vulnerable to vision loss and other adverse outcomes.Wills Eye Hospital (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 7, 2018 Category: Consumer Health News Tags: Ophthalmology Commentary Source Type: news

UH, Humana launch Humana Integrated Health System Sciences Institute
In September, Humana announced that it would donate $15 million to the university over 10 years in order to unite the UH College of Medicine and the existing colleges of nursing, pharmacy, social work and optometry. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 7, 2018 Category: Pharmaceuticals Authors: Chris Mathews Source Type: news

Minimally Invasive Surgery Works Well for Detached Retina
FRIDAY, Dec. 7, 2018 -- A minimally invasive treatment for retinal detachment leads to favorable outcomes, according to a study published online Nov. 20 in Ophthalmology. Roxane J. Hillier, M.B.Ch.B., from St. Michael's Hospital and the University... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 7, 2018 Category: Pharmaceuticals Source Type: news

Alimera Sciences wins Health Canada nod for diabetic macular edema implant
Alimera Sciences (NSDQ:ALIM) said last month that it won approval in Canada for its intravitreal implant designed to treat diabetic macular edema. The Iluvien device is a sustained release implant that delivers fluocinolone acetonide and is indicated to treat diabetic macular edema in people who have been previously given corticosteroids and did not have a clinically significant rise in intraocular pressure. Get the full story at our sister site, Drug Delivery Business News. The post Alimera Sciences wins Health Canada nod for diabetic macular edema implant appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance Wall Street Beat Alimera Sciences Knight Therapeutics Source Type: news

Bausch and Lomb Receives 510(K) Clearance From FDA For Bausch and Lomb Ultra(R) Multifocal For Astigmatism Contact Lenses
BRIDGEWATER, N.J., Dec. 5, 2018 -- (Healthcare Sales & Marketing Network) -- Bausch & Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that it has received 510(k) cleara... Devices, Ophthalmology, FDA Bausch & Lomb, Ultra Multifocal, Astigmatism, Contact Lens (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 5, 2018 Category: Pharmaceuticals Source Type: news

Children's Hospital celebrates European Commission approval of first-of-its-kind gene therapy for blindness
(Children's Hospital of Philadelphia) Children's Hospital of Philadelphia celebrates a pivotal moment in medicine: approval by the European Commission of LUXTURNA ® (voretigene neparvovec), the first and only gene therapy for patients with an inherited retinal disease, last month. This also makes LUXTURNA the first gene therapy for a genetic disease that has received regulatory approval in both the US and European Union. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 5, 2018 Category: International Medicine & Public Health Source Type: news

Many Patients Withhold Information From Clinicians
Reasons for nondisclosure include not wanting to be judged or lectured, being embarrassed (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 5, 2018 Category: Cancer & Oncology Tags: Cardiology, Dermatology, Endocrinology, Family Medicine, Geriatrics, Gastroenterology, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Emergency Medicine, Nephrology, Neurology, Nursing, Oncology, Ophthalmology, Orthopedics, ENT, Pediatrics, Psy Source Type: news

FDA clears Editas to test gene-editing drug in humans
The FDA has signed off on Cambridge startup Editas Medicine's plans to launch its first-ever clinical trial, which will make it among the first U.S. companies to test the gene editing technology CRISPR/Cas9 in humans. Editas (Nasdaq: EDIT) said that the FDA approved the launch of an early-stage trial of its drug for the most common cause of childhood blindness. The treatment uses CRISPR/Cas9, which allows scientists to replace or eliminate disease-causing segments of DNA. The study, which Editas… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 4, 2018 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

FDA clears Editas to test gene-editing drug in humans
The FDA has signed off on Cambridge startup Editas Medicine's plans to launch its first-ever clinical trial, which will make it among the first U.S. companies to test the gene editing technology CRISPR/Cas9 in humans. Editas (Nasdaq: EDIT) said that the FDA approved the launch of an early-stage trial of its drug for the most common cause of childhood blindness. The treatment uses CRISPR/Cas9, which allows scientists to replace or eliminate disease-causing segments of DNA. The study, which Editas… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 4, 2018 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

Reduce your risk of macular degeneration by a whopping 61% just by eating oranges
(Natural News) In the U.S., more people lose their vision because of age-related macular degeneration than glaucoma and cataracts combined, says the National Institute of Health (NIH). This makes the condition the leading cause of blindness among people older than 60. Macular degeneration is irreversible, but there are steps you can take to lower your... (Source: NaturalNews.com)
Source: NaturalNews.com - December 4, 2018 Category: Consumer Health News Source Type: news

Notal Vision snags breakthrough designation for home OCT system
Ophthalmic diagnostic services company Notal Vision said it has won breakthrough device designation for its artificial-intelligence-aided macular degeneration diagnostic device. Privately-held Notal (Manassas, Va.) said its home-based optical coherence tomography (OCT) system was designed to automatically identify intra- and/or subretinal fluid in the central 10 degrees of eyes diagnosed with exudative age-related macular degeneration (eAMD). The Notal Home OCT device is intended for testing at home between regularly scheduled clinic assessments and not intended to replace standard-of-care regularly schedule...
Source: Mass Device - December 4, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Business/Financial News Food & Drug Administration (FDA) Optical/Ophthalmic Vision Notal Vision Source Type: news

Eyenovia kicks off second Ph3 trial for pupil dilation tech
Eyenovia (NSDQ:EYEN) said this week that it finished patient enrollment in its Phase III Mist-1 trial and enrolled the first patient in its second Phase III trial for the company’s combination eye solution delivered as a micro-dose using its Optejet device. The company is studying the therapy for pharmacologic mydriasis – pupil dilation for eye exams. The process is used in roughly 80 million office-based eye exams each year in the U.S., according to Eyenovia. Get the full story at our sister site, Drug Delivery Business News. The post Eyenovia kicks off second Ph3 trial for pupil dilation tech appeared fi...
Source: Mass Device - December 4, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Eyenovia Inc. Source Type: news

Neuro-ophthalmologic disorders following concussion - Debacker J, Ventura R, Galetta SL, Balcer LJ, Rucker JC.
Visual symptoms, such as photophobia and blurred vision, are common in patients with concussion. Such symptoms may be accompanied by abnormalities of specific eye movements, such as saccades and convergence, or accommodation deficits. The high frequency of... (Source: SafetyLit)
Source: SafetyLit - December 4, 2018 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

FDA Approves Dextenza (dexamethasone ophthalmic insert) for the Treatment of Ocular Pain Following Ophthalmic Surgery
BEDFORD, Mass.--(BUSINESS WIRE)--Dec. 3, 2018-- Ocular Therapeutix™, Inc. a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 3, 2018 Category: Drugs & Pharmacology Source Type: news

FDA OKs Steroid Insert (Dextenza) for Postop Ocular Pain FDA OKs Steroid Insert (Dextenza) for Postop Ocular Pain
Dextenza is the first FDA-approved intracanalicular insert that delivers dexamethasone to treat ocular pain following ophthalmic surgery for up to 30 days with a single insertion.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 3, 2018 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news

FDA clears testing for another gene-editing drug in humans
The FDA has signed off on a Massachusetts startup's plans to launch its first-ever clinical trial, which will make it among the first U.S. companies to test the gene editing technology CRISPR/Cas9 in humans. Cambridge-based Editas Medicine (Nasdaq: EDIT) said Friday, Nov. 30, that the FDA had approved the launch of an early-stage trial of its drug for the most common cause of childhood blindness. The treatment uses CRISPR/Cas9, which allows scientists to replace or eliminate disease-causing segments… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 3, 2018 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

‘Breakthrough’ eye-pressure sensor trial begins in Germany
(Image courtesy of Implandata) Implandata Ophthalmic Products announced that the first patient in its international, multi-center, ARGOS-SC01 clinical study has been successfully implanted with its novel pressure sensor. This first-in-human clinical study is being conducted to validate the suprachoroidally placed Eyemate-SC, a sensor implant for continual monitoring of intraocular pressure (IOP). While Implandata’s already CE-marked Eyemate-IO intraocular sensor implant is intended for use in glaucoma patients undergoing cataract surgery, the Eyemate-SC device allows implantation in glaucoma patients not indicated fo...
Source: Mass Device - December 3, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Optical/Ophthalmic Research & Development Implandata Ophthalmic Products Source Type: news

Alfred Mann Foundation chairman looks outward to extend founder ’ s legacy
When medtech pioneer Alfred Mann died in February 2016, he left behind a rich legacy of pure innovation and patient impact spanning the breadth of healthcare, from cardiology to hearing impairment, blindness and diabetes that will improve the lives of patients for decades to come. Extending and advancing that legacy is now the mission of Dr. Robert Greenberg, who took over as the foundation’s chairman in July. Speaking ahead of his appearance next week at MassDevice.com’s DeviceTalks West event in Costa Mesa, Greenberg told us that he’s looking to expand the foundation’s reach into the early-st...
Source: Mass Device - December 3, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured Funding Roundup Alfred Mann Foundation DeviceTalks West Source Type: news

Ocular Therapeutix wins FDA nod for drug-delivery eye insert
Ocular Therapeutix (NSDQ:OCUL) said today that the FDA approved its resubmitted application Dextenza, an ocular insert designed to release dexamethasone to relieve pain following ophthalmic surgery. The regulatory win for the Bedford, Mass.-based company comes after much back-and-forth with the FDA; the agency has twice rejected Ocular Therapeutix’s application for Dextenza. Get the full story at our sister site, Drug Delivery Business News. The post Ocular Therapeutix wins FDA nod for drug-delivery eye insert appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 3, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pain Management Pharmaceuticals Regulatory/Compliance Wall Street Beat oculartherapeutix Source Type: news